Gastroesophageal Reflux Disease (GERD): Pathophysiology, Clinical Features, Diagnosis, and Evidence-Based Management

Gastroesophageal reflux disease (GERD) is a chronic disorder in which reflux of stomach contents into the esophagus causes troublesome symptoms and/or complications. The foundational problem is not simple “heartburn,” but a failure of normal antireflux defenses combined with factors that increase reflux burden and impair esophageal clearance. While physiologic reflux occurs in healthy individuals, GERD is defined clinically by the persistence, frequency, or severity of symptoms and the presence of mucosal injury.

At the core of GERD pathophysiology is dysfunction of the lower esophageal sphincter (LES). The LES normally prevents backflow of gastric contents. In GERD, LES pressure and reflex mechanisms are impaired, leading to increased transient LES relaxations—brief relaxations that permit reflux even when swallow-related mechanisms are absent. Structural and functional contributors include hiatal hernia, which allows part of the stomach to migrate above the diaphragm, reducing the effectiveness of the diaphragmatic pinch and altering the angle of the gastroesophageal junction. Gastric emptying delay and impaired gastric accommodation can raise intragastric volume and pressure, increasing the likelihood of reflux events.

Another key mechanism is esophageal clearance failure and tissue sensitivity. After reflux, esophageal peristalsis clears acid and gas; impaired clearance prolongs contact time with the esophageal mucosa. In addition, GERD symptoms are mediated by visceral hypersensitivity, where normal or mildly irritating refluxate triggers heightened perception. This explains why symptom severity does not always correlate linearly with acid exposure measured on testing. Non-acid reflux (e.g., bile, pepsin-containing material) can also contribute, particularly in refractory symptoms.

Clinically, GERD commonly presents with heartburn (retrosternal burning) and regurgitation, often worse after meals, when lying down, or with bending. “Typical” symptoms respond to acid suppression, but patients may also develop extraesophageal manifestations. These include chronic cough, hoarseness, globus sensation, laryngitis, asthma exacerbations, and dental erosions. The causal role of GERD in some extraesophageal syndromes is debated, but acid and non-acid reflux can provoke symptoms through mucosal irritation and neurogenic inflammation.

Complications of long-standing GERD include erosive esophagitis, peptic strictures due to chronic inflammation and fibrosis, and Barrett’s esophagus. Barrett’s esophagus is metaplastic replacement of normal squamous epithelium with intestinal-type columnar epithelium, occurring in response to chronic injury; it confers increased risk of esophageal adenocarcinoma. Alarm features—dysphagia, odynophagia, weight loss, gastrointestinal bleeding, anemia, or persistent vomiting—warrant prompt evaluation.

Diagnosis is primarily clinical, particularly for patients with classic symptoms and no alarm features. However, tests guide management when symptoms are atypical, refractory, or complicated. Upper endoscopy evaluates mucosal injury, detects strictures, and assesses for Barrett’s esophagus. Ambulatory reflux monitoring helps quantify acid exposure and symptoms association. For patients on proton pump inhibitors (PPIs) with ongoing symptoms, impedance-pH monitoring can detect both acid and non-acid reflux. Esophageal manometry is used to characterize motility disorders and to ensure safe selection of therapeutic options such as antireflux surgery.

Management begins with lifestyle measures that reduce reflux burden: weight loss in overweight patients, elevating the head of the bed, avoiding meals close to bedtime, and minimizing triggers such as high-fat meals, alcohol, and certain foods that worsen symptoms. While evidence varies by factor, these interventions are low risk and can improve symptom control.

Pharmacologic therapy typically escalates from H2-receptor antagonists to PPIs. PPIs suppress gastric acid secretion by inhibiting the H+/K+ ATPase in parietal cells and are the most effective medications for healing erosive esophagitis and controlling symptoms in most patients. Optimal PPI use involves timing before meals to align with proton pump activity. For persistent regurgitation, adjuncts such as alginate-based therapies or nighttime H2 blockers may be considered in selected patients. Prokinetic agents are not first-line due to limited efficacy and safety considerations.

For refractory GERD—persistent symptoms despite optimized PPI therapy—reassessment is essential. Clinicians should confirm adherence, correct dosing timing, evaluate for functional heartburn or esophageal hypersensitivity, and investigate non-acid reflux or alternative diagnoses such as eosinophilic esophagitis, infectious esophagitis, or cardiac conditions presenting as chest pain. Antireflux surgery (e.g., fundoplication) or endoscopic interventions may be appropriate for patients with confirmed GERD and objective evidence of reflux who have incomplete response to medications.

In summary, GERD is driven by LES dysfunction, increased reflux events, impaired clearance, and hypersensitivity, with clinical manifestations ranging from classic heartburn and regurgitation to extraesophageal symptoms and long-term complications such as Barrett’s esophagus. Evidence-based care integrates lifestyle modification, appropriately dosed acid suppression, and targeted diagnostic testing for refractory or complicated disease. Source: [Creator: @MenaMiroslav] (https://x.com/MenaMiroslav/status/2069007163008098432)